Sep 2026· Journal of Cardiovascular Development and Disease· Vol 13· 0 citations· 87 references
Medicine
TL;DR
This review critically examines the transformative role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL) and deep learning (DL), in redefining atherosclerosis management across three interconnected domains and explores how AI-driven predictive models integrate high-dimensional data to achieve superior cardiovascular risk stratification compared with conventional scores.
Abstract
Atherosclerosis remains a leading global cause of cardiovascular morbidity and mortality, yet its insidious progression and multifaceted etiology, spanning genetic, metabolic, and environmental determinants, often delay clinical recognition until adverse events occur. Traditional risk stratification tools, while foundational in preventive cardiology, are constrained by their reliance on limited variables and static linear assumptions, frequently misclassifying individuals at the extremes of risk. This review critically examines the transformative role of artificial intelligence (AI), particularly machine learning (ML) and deep learning (DL), in redefining atherosclerosis management across three interconnected domains. First, we explore how AI-driven predictive models integrate high-dimensional data, from genomics and imaging to real-time wearable metrics, to achieve superior cardiovascular risk stratification compared with conventional scores. Second, we detail AI’s capacity to automate and enhance plaque characterization through advanced imaging analysis, enabling reproducible quantification of burden, composition, and vulnerability markers that are imperceptible to human readers. Third, we investigate AI-powered clinical decision support systems, digital twins, and reinforcement learning approaches that facilitate dynamic, personalized treatment planning tailored to each patient’s evolving profile. We also critically address the ethical imperatives, algorithmic fairness, data privacy, transparency, and accountability, alongside practical challenges of clinical integration, regulatory validation, and health equity.
It is emphasized that successful integration of AI into cardiovascular care requires rigorous prospective validation, transparent algorithmic governance, equitable data representation, and human-AI collaborative frameworks, provided its meaningful clinical implication is demonstrated through improved patient outcomes.
Xu Xia, Wasim Ullah Khan, Q. Khan et al.· Trends in cardiovascular med...· 0 citations
Overall, AI outlines the transition from a reactive cardiology model toward a predictive, proactive, and precision-based approach in cardiovascular prevention, with a specific focus on risk stratification, early detection of subclinical disease, and identification of patients most likely to benefit from targeted interv...
Simona Giubilato, L. Granata, S. Petrina· Giornale italiano di cardiol...· 0 citations
ABSTRACT Cardiovascular diseases (CVDs) remain the leading cause of global mortality, and the burden is rising fastest in low‐ and middle‐income countries (LMICs). Conventional risk calculators, such as Framingham and Systematic Coronary Risk Evaluation (SCORE), incorporate age, blood pressure, cholesterol, diabetes an...
Sana Rasheed, Azka Mujeeb, M. Sarfraz et al.· Public Health Challenges· 0 citations
Atherosclerotic cardiovascular disease (ASCVD) is the leading global cause of death and evolves over decades through a prolonged subclinical phase, providing a critical opportunity for early detection and prevention. Traditional risk prediction models estimate future cardiovascular risk but may under- or overestimate i...
V. Sorin, Kemi Fatade, Michael F. Morris et al.· Radiographics· 0 citations
Overall, AI should be viewed as an assistive technology that may support earlier detection, more precise risk stratification, and scalable lifestyle management in prediabetes.
Run-Xuan Chen, Min Song, Tong Xiang· Frontiers in Endocrinology· 0 citations
Peripheral artery disease (PAD) is a prevalent atherosclerotic disorder affecting over 113 million individuals worldwide, with its global burden projected to rise substantially amid population aging and increasing metabolic comorbidities, including type 2 diabetes mellitus (T2DM). Conventional diagnostic assessment, in...
Bo Chen, Wan Chen, Xiao-Hua Yu et al.· Clinica chimica acta; intern...· 0 citations
Related blog posts
Microsoft Research Blog· microsoft.comNov 16, 2026
AI coding agents are increasingly help developers fix bugs and build features largely on their own, but every interaction with their models consumes tokens. In each session, an agent sends instructions, tool descriptions, and session history to its model. Most efforts to reduce this cost focus on individual tasks. Yet developers return to the same […] The post TokenEconomizer: Learning from Experience to Make AI Coding Agents More Efficient appeared first on Microsoft Research.
MIT News · Artificial Intelligence· news.mit.eduNov 9, 2026
A machine-learning approach called CheMeleon provides a practical way to develop new drugs or other molecules with much less detailed, expensive experimentation.
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.